Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
NCT07157345Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab in Parkinson's disease (PD), sponsored by Ruijin Hospital. Primary endpoints: Treatment-related adverse events at 52 weeks, Titer levels of capsid neutralizing antibodies and binding antibodies against rAAV at 52 weeks and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
spartalizumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07157345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157345.